S. Ferrari
New England Journal of Medicine · 2011–2018
A researcher in the Science corpus: 4 papers; trusts 0 researchers and is trusted by 3 researchers here, as inferred from the citation graph.
Who trusts S. Ferrari overall
Papers from S. Ferrari's perspective
Ordered by how strongly the researchers S. Ferrari trusts endorse each paper. Same corpus, a different order for every researcher.
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis (Journal of Bone and Mineral Research)
- The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. (New England Journal of Medicine)
- Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. (New England Journal of Medicine)
- Denosumab in postmenopausal women with low bone mineral density. (New England Journal of Medicine)
- Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. (Journal of oral and maxillofacial surgery)
- RANK-L and RANK: T cells, bone loss, and mammalian evolution. (Annual Review of Immunology)
- Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib (Journal of Bone and Mineral Research)
- Denosumab for prevention of fractures in postmenopausal women with osteoporosis. (New England Journal of Medicine)
- Osteoclast differentiation and activation (Nature)
- Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. (Cell Metabolism)
Their papers
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis. (2016) — 1,423 citations
- Denosumab and bisphosphonates: different mechanisms of action and effects. (2011) — 698 citations
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension (2018) — 626 citations
- Mechanisms of diabetes mellitus-induced bone fragility (2017) — 977 citations